Status: Not yet recruiting
Intrathecal Ziconotide in Chemotherapy Induced Peripheral Neuropathy
The purpose of this observational, data collection, research is to evaluate if ziconotide, a commercially approved medication given by a FDA cleared intrathecal pump, for chronic pain is effective in the treatment of chemotherapy-induced peripheral neuropathy (CIPN) a common and often long-lasting side effect of cancer treatment.
Participants needed: 24
Trial details
Age: 18-100Biological sex: AllType: ObservationalSponsor: Christian Hospital Northeast NorthwestUpdated: Mar 30, 2026Locations: 1
Eligibility criteria
Adult patients, ages 18-100, with chemotherapy-induced peripheral neuropathy as... [+4]
Patients with other forms of neuropathy (diabetic, idiopathic) will be excluded [+5]